Healius Limited (ASX:HLS)

Australia flag Australia · Delayed Price · Currency is AUD
1.505
+0.050 (3.44%)
May 1, 2025, 12:28 PM AEST
Market Cap 1.06B
Revenue (ttm) 1.79B
Net Income (ttm) -22.80M
Shares Out 726.13M
EPS (ttm) -0.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,094,287
Average Volume 2,579,851
Open 1.470
Previous Close 1.455
Day's Range 1.470 - 1.535
52-Week Range 1.080 - 1.860
Beta 0.63
RSI 59.77
Earnings Date May 21, 2025

About Healius

Healius Limited provides specialty diagnostic services to consumer and practitioners in Australia. The company operates through three segments: Pathology, Imaging, and Others. It offers diagnostic imaging services, private medical laboratory, and pathology services. The company provides services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetnostics, QML Pathology, TML Pathology, Abbott Pathology, IQ, Pathology, Kossard, Gastrolab, and Agilex Biolabs brands. It operates medi... [Read more]

Sector Healthcare
Founded 1994
Employees 9,658
Stock Exchange Australian Securities Exchange
Ticker Symbol HLS
Full Company Profile

Financial Performance

In 2024, Healius's revenue was 1.75 billion, an increase of 2.30% compared to the previous year's 1.71 billion. Losses were -645.80 million, 75.6% more than in 2023.

Financial Statements

News

There is no news available yet.